Citric acid/lactic acid/potassium bitartrate - Evofem

Drug Profile

Citric acid/lactic acid/potassium bitartrate - Evofem

Alternative Names: Acidform; Amphora; Amphora gel

Latest Information Update: 05 Jul 2017

Price : $50

At a glance

  • Originator Evofem
  • Class Anti-infectives; Contraceptives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Pregnancy
  • Phase I Bacterial vaginosis

Most Recent Events

  • 29 Jun 2017 Citric acid/lactic acid/potassium bitartrate - Evofem receives Qualified Infectious Disease Product status for Bacterial vaginosis (Prevention) in USA
  • 29 Jun 2017 Citric acid/lactic acid/potassium bitartrate - Evofem receives Qualified Infectious Disease Product status for Sexually transmitted infections (Prevention) in USA
  • 13 Apr 2017 Evofem plans a phase IIb trial for Chlamydia infection (Prevention) (NCT03107377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top